
Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.
1 June 2009
Irish biotech firm is reportedly discussing selling a minority-stake to Bristol-Myers Squibb.
According to a report in
In January, Elan hired Citigroup to conduct a strategic review of its business, which it said could lead to a sale or merger of the company.
Elan and Bristol-Myers Squibb declined to comment.
www.elan.com
www.bms.com






